beta

ALKS

Alkermes plc

Alks

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-14-2019 10-23-2018 07-26-2018 04-26-2018 02-14-2018 10-26-2017 07-27-2017 04-27-2017
Actual EPS 0.17 -0.08 0.09 -0.2 0.2 -0.09 -0.13 -0.31
Consensus EPS -0.32 -0.29 -0.11 -0.01 -0.15 -0.26 -0.24
Estimated EPS -0.32 -0.29 -0.11 -0.01 -0.15 -0.26 -0.24
Number of Estimates 2 2 2 2 3 1 2
EPS Surprise $0.49 $0.21 $0.20 $0.21 $0.06 $0.13 -$0.07

Stats

Summary

Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Market Cap: 9.2 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.alkermes.com

Shares Outstanding: 154 Million

Float: 152 Million

Dividend: 0.0 (0.0%)

Beta: 1.986142

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 11.6 Million

Ethical Flags

Animal testing

Longest drawdown: 1383 trading days

From: 2015-12-28 To: 2019-06-12

Lowest Point:

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

via: PR Newswire at 2019-06-12 03:00:00:000

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

via: PR Newswire at 2019-06-12 03:00:00:000

-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...

FDA Ad Com tomorrow on utility of higher-dose opioids

via: SeekingAlpha at 2019-06-10 13:06:51:000

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...

FDA Ad Com tomorrow on utility of higher-dose opioids

via: SeekingAlpha at 2019-06-10 13:06:51:000

The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

XBI: Biotech Performance And Valuation Update - June 2019

via: SeekingAlpha at 2019-06-03 05:30:25:000

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie… read more...

Biogen's MS candidate diroximel fumarate shows positive effect in late-stage study

via: SeekingAlpha at 2019-05-30 04:07:57:000

Updated interim data from an ongoing single-arm, open-label Phase 3 clinical trial, EVOLVE-MS-1 , evaluating Biogen's (NASDAQ: BIIB ) diroximel fumarate (DF)in patients with relapsing multiple sclerosis (MS) showed a treatment effect and favorable safety profile. The data were present… read more...

Biogen's MS candidate diroximel fumarate shows positive effect in late-stage study

via: SeekingAlpha at 2019-05-30 04:07:57:000

Updated interim data from an ongoing single-arm, open-label Phase 3 clinical trial, EVOLVE-MS-1 , evaluating Biogen's (NASDAQ: BIIB ) diroximel fumarate (DF)in patients with relapsing multiple sclerosis (MS) showed a treatment effect and favorable safety profile. The data were present… read more...

Biogen's MS candidate diroximel fumarate shows positive effect in late-stage study

via: SeekingAlpha at 2019-05-30 04:07:57:000

Updated interim data from an ongoing single-arm, open-label Phase 3 clinical trial, EVOLVE-MS-1 , evaluating Biogen's (NASDAQ: BIIB ) diroximel fumarate (DF)in patients with relapsing multiple sclerosis (MS) showed a treatment effect and favorable safety profile. The data were present… read more...

Biogen's MS candidate diroximel fumarate shows positive effect in late-stage study

via: SeekingAlpha at 2019-05-30 04:07:57:000

Updated interim data from an ongoing single-arm, open-label Phase 3 clinical trial, EVOLVE-MS-1 , evaluating Biogen's (NASDAQ: BIIB ) diroximel fumarate (DF)in patients with relapsing multiple sclerosis (MS) showed a treatment effect and favorable safety profile. The data were present… read more...

Walmart's 5260, Computex And Healthcare Headwinds (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-05-26 04:04:30:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Walmart's 5260, Computex And Healthcare Headwinds (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-05-26 04:04:30:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Walmart's 5260, Computex And Healthcare Headwinds (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-05-26 04:04:30:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Walmart's 5260, Computex And Healthcare Headwinds (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-05-26 04:04:30:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Stocks To Watch: Walmart's 5260, Computex And Healthcare Headwinds

via: SeekingAlpha at 2019-05-25 04:34:39:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. No formal trade talks are scheduled between the U.S. and China, but President Trump… read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-05-24 02:48:01:000

Noteworthy events during the week of May 26 - June 1 for healthcare investors. More news on: Nektar Therapeutics, Molina Healthcare, Inc., Axsome Therapeutics, Inc., Healthcare stocks news, , Read more … read more...

Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

via: PR Newswire at 2019-05-22 03:00:00:000

New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA and INVEGA SUSTENNA in Patients With Schizophrenia DUBLIN , May 22, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data f… read more...

Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting

via: PR Newswire at 2019-05-22 03:00:00:000

New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA and INVEGA SUSTENNA in Patients With Schizophrenia DUBLIN , May 22, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new data f… read more...

Retail On Display (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-05-19 03:35:57:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Retail On Display (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-05-19 03:35:57:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Retail On Display (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-05-19 03:35:57:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Stocks To Watch: Retail On Display

via: SeekingAlpha at 2019-05-18 03:41:57:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), … read more...

Alkermes to Present at the UBS Global Healthcare Conference

via: PR Newswire at 2019-05-14 12:01:00:000

DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 8:00 a.m. ET ( 1:00 p…. read more...

Alkermes to Present at the UBS Global Healthcare Conference

via: PR Newswire at 2019-05-14 12:01:00:000

DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 8:00 a.m. ET ( 1:00 p…. read more...

Alkermes to Present at the UBS Global Healthcare Conference

via: PR Newswire at 2019-05-14 12:01:00:000

DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 8:00 a.m. ET ( 1:00 p…. read more...

Alkermes to Present at the UBS Global Healthcare Conference

via: PR Newswire at 2019-05-14 12:01:00:000

DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 8:00 a.m. ET ( 1:00 p…. read more...

Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences

via: PR Newswire at 2019-05-13 03:00:00:000

-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings-- DUBLIN , May 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present data from its mental health portf… read more...

Alkermes Again: Best Odds Of Next 3+Month Biotech Price Gains

via: SeekingAlpha at 2019-05-08 08:19:43:000

Active investment management wins again This is a classic example with Alkermes, plc ( ALKS ) of an investing strategy which turns the "risk-terror" of price "volatility" into the productive work of being alert and using the disciplines of a clearly-stated (and followed) portfolio manageme… read more...

Alkermes Again: Best Odds Of Next 3+Month Biotech Price Gains

via: SeekingAlpha at 2019-05-08 08:19:43:000

Active investment management wins again This is a classic example with Alkermes, plc ( ALKS ) of an investing strategy which turns the "risk-terror" of price "volatility" into the productive work of being alert and using the disciplines of a clearly-stated (and followed) portfolio manageme… read more...

Alkermes Again: Best Odds Of Next 3+Month Biotech Price Gains

via: SeekingAlpha at 2019-05-08 08:19:43:000

Active investment management wins again This is a classic example with Alkermes, plc ( ALKS ) of an investing strategy which turns the "risk-terror" of price "volatility" into the productive work of being alert and using the disciplines of a clearly-stated (and followed) portfolio manageme… read more...

Alkermes Again: Best Odds Of Next 3+Month Biotech Price Gains

via: SeekingAlpha at 2019-05-08 08:19:43:000

Active investment management wins again This is a classic example with Alkermes, plc ( ALKS ) of an investing strategy which turns the "risk-terror" of price "volatility" into the productive work of being alert and using the disciplines of a clearly-stated (and followed) portfolio manageme… read more...

Alkermes Again: Best Odds Of Next 3+Month Biotech Price Gains

via: SeekingAlpha at 2019-05-08 08:19:43:000

Active investment management wins again This is a classic example with Alkermes, plc ( ALKS ) of an investing strategy which turns the "risk-terror" of price "volatility" into the productive work of being alert and using the disciplines of a clearly-stated (and followed) portfolio manageme… read more...

ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q1 2019

via: SeekingAlpha at 2019-05-01 04:49:00:000

Read more … read more...

ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q1 2019

via: SeekingAlpha at 2019-05-01 04:49:00:000

Read more … read more...

ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q1 2019

via: SeekingAlpha at 2019-05-01 04:49:00:000

Read more … read more...

ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q1 2019

via: SeekingAlpha at 2019-05-01 04:49:00:000

Read more … read more...

ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q1 2019

via: SeekingAlpha at 2019-05-01 04:49:00:000

Read more … read more...

ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q1 2019

via: SeekingAlpha at 2019-05-01 04:49:00:000

Read more … read more...

ClearBridge Large Cap Growth ESG Strategy Portfolio Manager Commentary Q1 2019

via: SeekingAlpha at 2019-05-01 04:49:00:000

Read more … read more...

Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short

via: SeekingAlpha at 2019-04-26 09:01:07:000

Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th… read more...

Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short

via: SeekingAlpha at 2019-04-26 09:01:07:000

Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th… read more...

Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short

via: SeekingAlpha at 2019-04-26 09:01:07:000

Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th… read more...

Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short

via: SeekingAlpha at 2019-04-26 09:01:07:000

Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th… read more...

Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short

via: SeekingAlpha at 2019-04-26 09:01:07:000

Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th… read more...

Alkermes plc (ALKS) CEO Richard Pops on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-04-25 11:39:18:000

Alkermes plc (ALKS) Q1 2019 Earnings Conference Call April 25, 2019 8:30 A.M. ET Company Participants Sandy Coombs - Vice President, Investor Relations Jim Frates - Chief Financial Officer Craig Hopkinson - Chief Medical Officer Richard Pops - Chief Executive Officer Confere… read more...

Alkermes plc 2019 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-04-25 06:01:59:000

The following slide deck was published by Alkermes plc in conjunction with their 2019 Q1 earnings Read more … read more...

Alkermes Q1 top line off 1%; reiterates guidance

via: SeekingAlpha at 2019-04-25 05:33:54:000

Alkermes ( ALKS ) Q1 results : Revenues: $223.1M (-0.9%); Manufacturing and royalty revenues: $108.9M (-5.0%); Product sales: $99.5M (8.4%); R&D revenue: $14.7M (-21.4%). More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Alkermes EPS in-line, beats on revenue

via: SeekingAlpha at 2019-04-25 03:03:31:000

Alkermes (NASDAQ: ALKS ): Q1 Non-GAAP EPS of -$0.17 in-line; GAAP EPS of -$0.62. More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports First Quarter 2019 Financial Results

via: PR Newswire at 2019-04-25 03:00:00:000

First Quarter Revenues of $223.1 Million , Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports GAAP Net Loss per Share of $0.62 and Non-GAAP Net Loss per Share of $0…. read more...

Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

via: PR Newswire at 2019-04-24 12:01:00:000

DUBLIN , April 24, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announcedthat C. Todd Nichols , an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's Senior Vice President of Sales and … read more...

First exec indicted over role in opioid crisis

via: SeekingAlpha at 2019-04-23 08:26:30:000

Laurence Doud III, former CEO of Rochester Drug Co-Operative, was indicted yesterday by a Manhattan federal grand jury on charges of narcotics conspiracy and conspiracy to defraud the Drug Enforcement Administration (DEA) related to the distribution of "tens of millions" of opioid painkill… read more...

Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

via: PR Newswire at 2019-04-18 12:00:00:000

DUBLIN , April 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's first quarter 2019 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

via: PR Newswire at 2019-04-18 12:00:00:000

DUBLIN , April 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's first quarter 2019 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

via: PR Newswire at 2019-04-18 12:00:00:000

DUBLIN , April 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's first quarter 2019 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

via: PR Newswire at 2019-04-18 12:00:00:000

DUBLIN , April 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's first quarter 2019 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

via: PR Newswire at 2019-04-18 12:00:00:000

DUBLIN , April 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's first quarter 2019 financial results. Management will also provide an … read more...

DOJ charges 31 docs for over-prescribing opioids

via: SeekingAlpha at 2019-04-17 09:58:09:000

The U.S. Depart of Justice has charged 60 people , including 31 physicians, with illegally prescribing and distributing opioid painkillers. The DOJ claims that the group, which includes 53 medical professionals, are tied to ~350K prescriptions and 32M pills. More news on: Endo Internation… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes' Aristada on par with J&J's Invega Sustenna in schizophrenia study

via: SeekingAlpha at 2019-04-09 03:26:01:000

Results from a Phase 3b clinical trial, ALPINE , evaluating Alkermes plc's (NASDAQ: ALKS ) ARISTADA (aripiprazole lauroxil) and Johnson & Johnson (NYSE: JNJ ) unit Janssen Pharmaceuticals' INVEGA SUSTENNA (paliperidone palmitate) in 200 patients experiencing acute exacerbations of sc… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

via: PR Newswire at 2019-04-09 03:00:00:000

-- Large, randomized ALPINE trial showed both long-acting injectable medicationseffectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar efficacy to current market-leader INVEGA SUSTENNA, with differences in safet… read more...

Alkermes Announces Departure of Jim Robinson

via: PR Newswire at 2019-04-08 13:15:00:000

DUBLIN , April 8, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson , President and Chief Operating Officer, has resigned from his position and will leave the company, effective April 19, 2019 , for personal reasons. "The past year has be… read more...

Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

via: PR Newswire at 2019-04-03 03:00:00:000

DUBLIN , April 3, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDS SM program, an initiative designed to support the next generation of researchers who are working on the front lines to advance u… read more...

Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

via: PR Newswire at 2019-04-03 03:00:00:000

DUBLIN , April 3, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDS SM program, an initiative designed to support the next generation of researchers who are working on the front lines to advance u… read more...

Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

via: PR Newswire at 2019-04-03 03:00:00:000

DUBLIN , April 3, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDS SM program, an initiative designed to support the next generation of researchers who are working on the front lines to advance u… read more...

Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

via: PR Newswire at 2019-04-03 03:00:00:000

DUBLIN , April 3, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDS SM program, an initiative designed to support the next generation of researchers who are working on the front lines to advance u… read more...

Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia

via: PR Newswire at 2019-04-03 03:00:00:000

DUBLIN , April 3, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDS SM program, an initiative designed to support the next generation of researchers who are working on the front lines to advance u… read more...

Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society

via: PR Newswire at 2019-04-01 03:00:00:000

Company to Host Investor Conference Call at 8:00 a.m. ET on Friday , April 12 Poster Presentations to Highlight New Data on ARISTADA and ALKS 3831 DUBLIN , April 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq:… read more...

Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society

via: PR Newswire at 2019-04-01 03:00:00:000

Company to Host Investor Conference Call at 8:00 a.m. ET on Friday , April 12 Poster Presentations to Highlight New Data on ARISTADA and ALKS 3831 DUBLIN , April 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq:… read more...

FDA OKs Merck KGaA's MS med Mavenclad

via: SeekingAlpha at 2019-03-30 13:00:54:000

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more … read more...

FDA OKs Merck KGaA's MS med Mavenclad

via: SeekingAlpha at 2019-03-30 13:00:54:000

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more … read more...

FDA's Gottlieb proposes higher standard for future opioid approvals

via: SeekingAlpha at 2019-03-28 12:55:32:000

In testimony before a Senate Appropriations Subcommittee about the FDA's 2020 budget request, Commissioner Scott Gottlieb, M.D. emphasized the importance of a relatively paltry additional $55M to continue the agency's work combating the opioid crisis. More news on: Endo International plc… read more...

FDA's Gottlieb proposes higher standard for future opioid approvals

via: SeekingAlpha at 2019-03-28 12:55:32:000

In testimony before a Senate Appropriations Subcommittee about the FDA's 2020 budget request, Commissioner Scott Gottlieb, M.D. emphasized the importance of a relatively paltry additional $55M to continue the agency's work combating the opioid crisis. More news on: Endo International plc… read more...

FDA OKs Novartis' MS med Mayzent

via: SeekingAlpha at 2019-03-27 03:22:46:000

The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio… read more...

Purdue Pharma settles opioid case in OK for $270M

via: SeekingAlpha at 2019-03-26 08:39:24:000

Privately held Purdue Pharma LP has agreed to pay the state of Oklahoma $270M to settle litigation from the AG's office over its role in the opioid crisis there. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, Stocks on… read more...

3 Biotech Stocks Insiders Are Buying

via: SeekingAlpha at 2019-03-22 13:57:44:000

Life is either a daring adventure or nothing at all. - Helen Keller Today, we take a look at three small biotech stocks that are seeing some recent insider buying. I have always viewed insider buying as a positive when evaluating stocks in different sectors. Given the complexity … read more...

3 Biotech Stocks Insiders Are Buying

via: SeekingAlpha at 2019-03-22 13:57:44:000

Life is either a daring adventure or nothing at all. - Helen Keller Today, we take a look at three small biotech stocks that are seeing some recent insider buying. I have always viewed insider buying as a positive when evaluating stocks in different sectors. Given the complexity … read more...

3 Biotech Stocks Insiders Are Buying

via: SeekingAlpha at 2019-03-22 13:57:44:000

Life is either a daring adventure or nothing at all. - Helen Keller Today, we take a look at three small biotech stocks that are seeing some recent insider buying. I have always viewed insider buying as a positive when evaluating stocks in different sectors. Given the complexity … read more...

3 Biotech Stocks Insiders Are Buying

via: SeekingAlpha at 2019-03-22 13:57:44:000

Life is either a daring adventure or nothing at all. - Helen Keller Today, we take a look at three small biotech stocks that are seeing some recent insider buying. I have always viewed insider buying as a positive when evaluating stocks in different sectors. Given the complexity … read more...

Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development

via: Business Wire at 2019-03-20 05:00:00:000

Group Aims to Bring Disease-Associated Biomarker Through FDAs Drug Development Tools Qualification Program The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to… read more...

Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development

via: Business Wire at 2019-03-20 05:00:00:000

Group Aims to Bring Disease-Associated Biomarker Through FDAs Drug Development Tools Qualification Program The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to… read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Canada to institute tighter restrictions on opioid marketing

via: SeekingAlpha at 2019-03-11 08:02:44:000

Effective in June, Health Canada will institute new regulations related to the marketing of Class B opioids, a class of painkillers equal to or stronger than morphine. More news on: Endo International plc, INSYS Therapeutics, Inc., Titan Pharmaceuticals, Inc., Healthcare stocks news, … read more...

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

via: PR Newswire at 2019-03-05 11:01:00:000

DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET ( 12:40 p.m. GMT ) from Boston . The … read more...

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

via: PR Newswire at 2019-03-05 11:01:00:000

DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET ( 12:40 p.m. GMT ) from Boston . The … read more...

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

via: PR Newswire at 2019-03-05 11:01:00:000

DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET ( 12:40 p.m. GMT ) from Boston . The … read more...

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

via: PR Newswire at 2019-03-05 11:01:00:000

DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET ( 12:40 p.m. GMT ) from Boston . The … read more...

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

via: PR Newswire at 2019-03-05 11:01:00:000

DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET ( 12:40 p.m. GMT ) from Boston . The … read more...

Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

via: PR Newswire at 2019-03-05 11:01:00:000

DUBLIN , March 5, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39 th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET ( 12:40 p.m. GMT ) from Boston . The … read more...

Painkiller stocks in the red on possible Purdue bankruptcy

via: SeekingAlpha at 2019-03-04 08:14:42:000

The broad market's down day notwithstanding, opioid drugmakers are under modest pressure in apparent response to a report that privately held Purdue Pharma is mulling a Chapter 11 bankruptcy filing to protect itself from the ~2,000 lawsuits against it related to its marketing practices for… read more...

Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

via: PR Newswire at 2019-02-26 07:00:00:000

DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with… read more...

Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

via: PR Newswire at 2019-02-26 07:00:00:000

DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with… read more...

Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

via: PR Newswire at 2019-02-26 07:00:00:000

DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with… read more...

Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

via: PR Newswire at 2019-02-26 02:00:00:000

DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with… read more...

Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

via: PR Newswire at 2019-02-26 02:00:00:000

DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with… read more...

Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

via: PR Newswire at 2019-02-26 02:00:00:000

DUBLIN , Feb. 26, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-2, a new clinical study of ALKS 4230 administered subcutaneously as monotherapy and in combination with the PD-1 inhibitor KEYTRUDA (pembrolizumab) in patients with… read more...

FDA accepts Alkermes's and Biogen's NDA for BIIB098 for MS

via: SeekingAlpha at 2019-02-25 07:54:49:000

The FDA has accepted for review Alkermes' (NASDAQ: ALKS ) and Biogen's (NASDAQ: BIIB ) New Drug Application (NDA) for diroximel fumarate (BIIB098), an oral fumarate in development for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Biogen Inc., Alkermes plc, He… read more...

Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

via: PR Newswire at 2019-02-25 07:30:00:000

DUBLIN and CAMBRIDGE, Mass. , Feb. 25, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc.(Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate(BII… read more...

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

DUBLIN , Feb. 20, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the SVB Leerink Global Healthcare Conferenceon Wednesday, Feb. 27, 2019 at 2:30 p.m. ET ( 7:30 p.m. … read more...

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

DUBLIN , Feb. 20, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the SVB Leerink Global Healthcare Conferenceon Wednesday, Feb. 27, 2019 at 2:30 p.m. ET ( 7:30 p.m. … read more...

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

DUBLIN , Feb. 20, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the SVB Leerink Global Healthcare Conferenceon Wednesday, Feb. 27, 2019 at 2:30 p.m. ET ( 7:30 p.m. … read more...

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

DUBLIN , Feb. 20, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the SVB Leerink Global Healthcare Conferenceon Wednesday, Feb. 27, 2019 at 2:30 p.m. ET ( 7:30 p.m. … read more...

Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

via: PR Newswire at 2019-02-20 16:01:00:000

DUBLIN , Feb. 20, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the SVB Leerink Global Healthcare Conferenceon Wednesday, Feb. 27, 2019 at 2:30 p.m. ET ( 7:30 p.m. … read more...

Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies

via: PR Newswire at 2019-02-19 07:00:00:000

-- Combinations of ALKS 4230 with Rucaparib and Lucitanib to be Evaluated in Multiple Preclinical Tumor Models -- DUBLIN and BOULDER, Colorado , Feb. 19, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that the companies … read more...

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Start Time: 08:30 End Time: 09:37 Alkermes plc (ALKS) Q4 2018 Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants Richard Pops - Chairman and CEO Jim Frates - SVP and CFO Jim Robinson - President and COO Sandy Coombs - Senior Director of IR Confe… read more...

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Start Time: 08:30 End Time: 09:37 Alkermes plc (ALKS) Q4 2018 Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants Richard Pops - Chairman and CEO Jim Frates - SVP and CFO Jim Robinson - President and COO Sandy Coombs - Senior Director of IR Confe… read more...

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Start Time: 08:30 End Time: 09:37 Alkermes plc (ALKS) Q4 2018 Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants Richard Pops - Chairman and CEO Jim Frates - SVP and CFO Jim Robinson - President and COO Sandy Coombs - Senior Director of IR Confe… read more...

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Start Time: 08:30 End Time: 09:37 Alkermes plc (ALKS) Q4 2018 Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants Richard Pops - Chairman and CEO Jim Frates - SVP and CFO Jim Robinson - President and COO Sandy Coombs - Senior Director of IR Confe… read more...

Alkermes plc (ALKS) CEO Richard Pops on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-14 17:06:39:000

Start Time: 08:30 End Time: 09:37 Alkermes plc (ALKS) Q4 2018 Earnings Conference Call February 14, 2019, 08:30 AM ET Company Participants Richard Pops - Chairman and CEO Jim Frates - SVP and CFO Jim Robinson - President and COO Sandy Coombs - Senior Director of IR Confe… read more...

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

NEW YORK , Feb.14, 2019 /PRNewswire/ -- Arlo Technologies, Inc. (ARLO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that shipment of Arlo's Ultra camera would be delayed due to "a quality issue… read more...

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

NEW YORK , Feb.14, 2019 /PRNewswire/ -- Arlo Technologies, Inc. (ARLO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that shipment of Arlo's Ultra camera would be delayed due to "a quality issue… read more...

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

NEW YORK , Feb.14, 2019 /PRNewswire/ -- Arlo Technologies, Inc. (ARLO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that shipment of Arlo's Ultra camera would be delayed due to "a quality issue… read more...

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

NEW YORK , Feb.14, 2019 /PRNewswire/ -- Arlo Technologies, Inc. (ARLO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that shipment of Arlo's Ultra camera would be delayed due to "a quality issue… read more...

Lifshitz & Miller LLP Announces Investigation of Arlo Technologies, Inc., Alkermes Public Limited Company, Lexicon Pharmaceuticals, Inc., BSB Bancorp, Inc., Markel Corporation, Natural Health Trends Corp., and Nova Lifestyle, Inc.

via: PR Newswire at 2019-02-14 13:39:00:000

NEW YORK , Feb.14, 2019 /PRNewswire/ -- Arlo Technologies, Inc. (ARLO) Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that shipment of Arlo's Ultra camera would be delayed due to "a quality issue… read more...

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes ( ALKS ) Q4 results : Revenues: $315.8M (+14.7%); Manufacturing and royalty revenues: $167.4M (+20.7%); Product sales: $132.7M (+27.7%); R&D revenue: $15.6M; License revenues: $0.1M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read mo… read more...

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes ( ALKS ) Q4 results : Revenues: $315.8M (+14.7%); Manufacturing and royalty revenues: $167.4M (+20.7%); Product sales: $132.7M (+27.7%); R&D revenue: $15.6M; License revenues: $0.1M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read mo… read more...

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes ( ALKS ) Q4 results : Revenues: $315.8M (+14.7%); Manufacturing and royalty revenues: $167.4M (+20.7%); Product sales: $132.7M (+27.7%); R&D revenue: $15.6M; License revenues: $0.1M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read mo… read more...

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes ( ALKS ) Q4 results : Revenues: $315.8M (+14.7%); Manufacturing and royalty revenues: $167.4M (+20.7%); Product sales: $132.7M (+27.7%); R&D revenue: $15.6M; License revenues: $0.1M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read mo… read more...

Alkermes Q4 top line up 15%

via: SeekingAlpha at 2019-02-14 09:24:01:000

Alkermes ( ALKS ) Q4 results : Revenues: $315.8M (+14.7%); Manufacturing and royalty revenues: $167.4M (+20.7%); Product sales: $132.7M (+27.7%); R&D revenue: $15.6M; License revenues: $0.1M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read mo… read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes plc 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-14 08:29:14:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q4 earnings Read more … read more...

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes (NASDAQ: ALKS ): Q4 Non-GAAP EPS of $0.34 beats by $0.38 ; GAAP EPS of -$0.06 beats by $0.38 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes (NASDAQ: ALKS ): Q4 Non-GAAP EPS of $0.34 beats by $0.38 ; GAAP EPS of -$0.06 beats by $0.38 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes (NASDAQ: ALKS ): Q4 Non-GAAP EPS of $0.34 beats by $0.38 ; GAAP EPS of -$0.06 beats by $0.38 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes (NASDAQ: ALKS ): Q4 Non-GAAP EPS of $0.34 beats by $0.38 ; GAAP EPS of -$0.06 beats by $0.38 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.38, beats on revenue

via: SeekingAlpha at 2019-02-14 07:05:34:000

Alkermes (NASDAQ: ALKS ): Q4 Non-GAAP EPS of $0.34 beats by $0.38 ; GAAP EPS of -$0.06 beats by $0.38 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports 2018 GAAP Net Loss per Share of $0.90 and Diluted Non-GAAP Earnings per Share of $0.61 &#xA… read more...

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports 2018 GAAP Net Loss per Share of $0.90 and Diluted Non-GAAP Earnings per Share of $0.61 &#xA… read more...

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports 2018 GAAP Net Loss per Share of $0.90 and Diluted Non-GAAP Earnings per Share of $0.61 &#xA… read more...

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports 2018 GAAP Net Loss per Share of $0.90 and Diluted Non-GAAP Earnings per Share of $0.61 &#xA… read more...

Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019

via: PR Newswire at 2019-02-14 07:00:00:000

Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports 2018 GAAP Net Loss per Share of $0.90 and Diluted Non-GAAP Earnings per Share of $0.61 &#xA… read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, (Alkermes or the Company) (NASDAQ:&… read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, (Alkermes or the Company) (NASDAQ:&… read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, (Alkermes or the Company) (NASDAQ:&… read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, (Alkermes or the Company) (NASDAQ:&… read more...

Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS)

via: Business Wire at 2019-02-13 21:48:00:000

Glancy Prongay & Murray LLP (GPM)reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, (Alkermes or the Company) (NASDAQ:&… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2019-02-13 17:30:30:000

AAN , AEE , AER , AGIO , ALE , ALKS , ARCH , AVP , AZN , BAM , BCOR , BGCP , BLMN , BWA , CBB , CCEP , CME , COWN , CYBR , DGX , DNOW , DUK , EEX , EPAM , EQM , EQT , FAF , GEO , GLOG , GNRC , GOOS , GTLS , HII , HPP , INCY , IQV , IRM , KO , LECO , M… read more...

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS)

via: Business Wire at 2019-02-12 16:11:00:000

Law Offices of Howard G. Smithreminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc. (Alkermes or the Company) (NASDAQ: ALKS ) securities b… read more...

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS)

via: Business Wire at 2019-02-12 16:11:00:000

Law Offices of Howard G. Smithreminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc. (Alkermes or the Company) (NASDAQ: ALKS ) securities b… read more...

Alkermes Is Still An Attractive Pick

via: SeekingAlpha at 2019-02-11 14:22:50:000

The past few days have proved to be disappointing for the mental health and addiction-focused company, Alkermes ( ALKS ), with share prices slumping down by almost 6.74% from $33.08 on February 1. This month opened with the company receiving complete response letter or CRL from FDA related t… read more...

Best Odds Of Good Capital Gain In Next 3 Months

via: SeekingAlpha at 2019-02-11 12:42:46:000

You are, or should be, an odds-player And you need a good source of odds-ranking. The Daily Racing Form wont do it. Stock price handicappers are much more likely to be that source than the Wall Street Journal or Investors Daily. But the handicappers dont publish anythin… read more...

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

DUBLIN , Feb. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Feb. 14, 2019 , to discuss the company's fourth quarter and year-end2018 financial results. Management will… read more...

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

DUBLIN , Feb. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Feb. 14, 2019 , to discuss the company's fourth quarter and year-end2018 financial results. Management will… read more...

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

DUBLIN , Feb. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Feb. 14, 2019 , to discuss the company's fourth quarter and year-end2018 financial results. Management will… read more...

Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results

via: PR Newswire at 2019-02-07 16:01:00:000

DUBLIN , Feb. 7, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Feb. 14, 2019 , to discuss the company's fourth quarter and year-end2018 financial results. Management will… read more...

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Alkermes plc, Inc. Investors (ALKS)

via: Business Wire at 2019-02-06 11:00:00:000

Glancy Prongay & Murray LLP (GPM), a global investors rights law firm,announces that a class action lawsuit has been filed on behalf of investors that acquired Alkermes plc, Inc. (Alkermes or the Company) (NASDAQ: ALKS ) securities… read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alkermes plc, Inc. Investors (ALKS)

via: Business Wire at 2019-02-05 19:03:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Alkermes plc, Inc. (NASDAQ: ALKS ) (Alkermes or the Company) securities between February 17, 2017 and November 1, 2018 , inclusive … read more...

Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alkermes plc, Inc. Investors (ALKS)

via: Business Wire at 2019-02-05 19:03:00:000

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased Alkermes plc, Inc. (NASDAQ: ALKS ) (Alkermes or the Company) securities between February 17, 2017 and November 1, 2018 , inclusive … read more...

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

Alkermes plc (NASDAQ: ALKS ) has received a CRL in response to its marketing application seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

Alkermes plc (NASDAQ: ALKS ) has received a CRL in response to its marketing application seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

Alkermes plc (NASDAQ: ALKS ) has received a CRL in response to its marketing application seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

Alkermes plc (NASDAQ: ALKS ) has received a CRL in response to its marketing application seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours

via: SeekingAlpha at 2019-02-01 16:10:15:000

Alkermes plc (NASDAQ: ALKS ) has received a CRL in response to its marketing application seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

DUBLIN , Feb. 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461 for theadjunctive treatment of major dep… read more...

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

DUBLIN , Feb. 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461 for theadjunctive treatment of major dep… read more...

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

DUBLIN , Feb. 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461 for theadjunctive treatment of major dep… read more...

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

DUBLIN , Feb. 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461 for theadjunctive treatment of major dep… read more...

Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application

via: PR Newswire at 2019-02-01 16:01:00:000

DUBLIN , Feb. 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461 for theadjunctive treatment of major dep… read more...

Biotech Bio Series #5: Stay Clear Of Biogen

via: SeekingAlpha at 2019-01-28 20:00:43:000

This is the fifth article of the Biotech Bio Series. Pharmaceuticals and biotechnology are some of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug… read more...

Biotech Bio Series #5: Stay Clear Of Biogen

via: SeekingAlpha at 2019-01-28 20:00:43:000

This is the fifth article of the Biotech Bio Series. Pharmaceuticals and biotechnology are some of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug… read more...

Biotech Bio Series #5: Stay Clear Of Biogen

via: SeekingAlpha at 2019-01-28 20:00:43:000

This is the fifth article of the Biotech Bio Series. Pharmaceuticals and biotechnology are some of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug… read more...

New Hope For Acorda Therapeutics In 2019

via: SeekingAlpha at 2019-01-28 16:07:55:000

Photo Credit: Biomed Realty Recommendation I recommend long Acorda Therapeutics ( ACOR ) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion,… read more...

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important February 25th Deadline - ALKS

via: PR Newswire at 2019-01-25 18:48:00:000

NEW YORK , Jan. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ: ALKS) from February 17, 2017 through November 1, 2018 , inclus… read more...

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important February 25th Deadline - ALKS

via: PR Newswire at 2019-01-25 18:48:00:000

NEW YORK , Jan. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ: ALKS) from February 17, 2017 through November 1, 2018 , inclus… read more...

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors with $100K in Losses of Important February 25th Deadline - ALKS

via: PR Newswire at 2019-01-25 18:48:00:000

NEW YORK , Jan. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ: ALKS) from February 17, 2017 through November 1, 2018 , inclus… read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-25 16:39:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-25 16:39:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-25 16:39:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-01-25 07:35:12:000

Noteworthy events during the week of January 27 - February 2 for healthcare investors. More news on: ProQR Therapeutics, GeoVax Labs, Inc., Sierra Oncology, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-01-25 07:35:12:000

Noteworthy events during the week of January 27 - February 2 for healthcare investors. More news on: ProQR Therapeutics, GeoVax Labs, Inc., Sierra Oncology, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-01-25 07:35:12:000

Noteworthy events during the week of January 27 - February 2 for healthcare investors. More news on: ProQR Therapeutics, GeoVax Labs, Inc., Sierra Oncology, Inc., Healthcare stocks news, , Read more … read more...

Jefferies bearish on biotechs, sees 6% near-term downside

via: SeekingAlpha at 2019-01-23 14:05:04:000

Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )… read more...

Jefferies bearish on biotechs, sees 6% near-term downside

via: SeekingAlpha at 2019-01-23 14:05:04:000

Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )… read more...

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...

Study links opioid prescriptions to marketing spend

via: SeekingAlpha at 2019-01-18 12:43:55:000

A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo… read more...

Massachusetts AG after Purdue Pharma owners for role in opioid crisis

via: SeekingAlpha at 2019-01-16 07:43:42:000

Massachusetts Attorney General Maura Healey has filed an amended lawsuit against privately held Purdue Pharma aimed at holding members of the controlling Sackler family personally responsible for its role in the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIV… read more...

Massachusetts AG after Purdue Pharma owners for role in opioid crisis

via: SeekingAlpha at 2019-01-16 07:43:42:000

Massachusetts Attorney General Maura Healey has filed an amended lawsuit against privately held Purdue Pharma aimed at holding members of the controlling Sackler family personally responsible for its role in the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIV… read more...

Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

via: PR Newswire at 2019-01-16 07:00:00:000

2018 Competitive Grants Program Awards Approximately $400,000 for Research Projects Focused on Substance Use Disorders DUBLIN , Jan. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the ALKERMES PATHWAYS RESEARCH AWA… read more...

Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

via: PR Newswire at 2019-01-16 07:00:00:000

2018 Competitive Grants Program Awards Approximately $400,000 for Research Projects Focused on Substance Use Disorders DUBLIN , Jan. 16, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of the ALKERMES PATHWAYS RESEARCH AWA… read more...

SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)

via: PR Newswire at 2019-01-10 16:04:00:000

PHILADELPHIA , Jan. 10, 2019 /PRNewswire/ --Berger Montague announced today that Alkermes (NASDAQ: ALKS) and its CEO and CFO have been accused of federal securities law violations in a class action filed in the U.S. District Court for the Eastern District of New York . The lawsuit … read more...

SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)

via: PR Newswire at 2019-01-10 16:04:00:000

PHILADELPHIA , Jan. 10, 2019 /PRNewswire/ --Berger Montague announced today that Alkermes (NASDAQ: ALKS) and its CEO and CFO have been accused of federal securities law violations in a class action filed in the U.S. District Court for the Eastern District of New York . The lawsuit … read more...

SHAREHOLDER ALERT: Berger Montague Announces Investigation of Alkermes, plc (NASDAQ: ALKS) (CUSIP: G01767105)

via: PR Newswire at 2019-01-10 16:04:00:000

PHILADELPHIA , Jan. 10, 2019 /PRNewswire/ --Berger Montague announced today that Alkermes (NASDAQ: ALKS) and its CEO and CFO have been accused of federal securities law violations in a class action filed in the U.S. District Court for the Eastern District of New York . The lawsuit … read more...

Alkermes (ALKS) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 05:56:26:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes (ALKS) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 05:56:26:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes (ALKS) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2019-01-10 05:56:26:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm

via: Business Wire at 2019-01-09 09:48:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS). If you invested in Alkermes stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/AL… read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkermes plc - ALKS

via: PR Newswire at 2019-01-08 19:47:00:000

NEW YORK , Jan. 9, 2019 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors ofAlkermes plc ("Alkermes" or the "Company")(NASDAQ: ALKS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 8… read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Alkermes plc to Contact the Firm

via: Business Wire at 2019-01-08 12:18:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS). If you invested in Alkermes stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/AL… read more...

Robbins Arroyo LLP: Alkermes Public Limited Company (ALKS) Misled Shareholders According to a Recently Filed Class Action

via: Business Wire at 2019-01-08 12:08:00:000

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Alkermes Public Limited Company (NASDAQ: ALKS) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 17, 2017 and November 1, 2018. Al… read more...

Investor Alert: Kaplan Fox Announces Investigation Of Alkermes plc

via: PR Newswire at 2019-01-08 10:36:00:000

NEW YORK , Jan. 8, 2019 /PRNewswire/ --Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS). Investors who purchased Alkermes securities between February 17, 2017 and… read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes plc To Contact The Firm

via: PR Newswire at 2019-01-07 13:49:00:000

NEW YORK , Jan. 7, 2019 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS). If you invested in Alkermes stock or options and would like to discuss… read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-04 12:46:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of… read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-04 12:46:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of… read more...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-04 12:46:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of… read more...

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2019-01-03 16:53:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Exchange Act of… read more...

Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare Conference

via: PR Newswire at 2019-01-02 16:00:00:000

DUBLIN , Jan. 2, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 at 9:30 a.m. PT ( 12:30 p.m. ET / 5:30 p.m. GMT ) from the We… read more...

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm,announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes plc("Alkermes" or the "… read more...

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm,announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes plc("Alkermes" or the "… read more...

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm,announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes plc("Alkermes" or the "… read more...

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm,announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes plc("Alkermes" or the "… read more...

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes plc - ALKS

via: PR Newswire at 2018-12-28 10:40:00:000

NEW YORK , Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm,announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes plc("Alkermes" or the "… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the Class Period). The lawsu… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the Class Period). The lawsu… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the Class Period). The lawsu… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the Class Period). The lawsu… read more...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

via: Business Wire at 2018-12-27 21:07:00:000

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the Class Period). The lawsu… read more...

Alkermes cut to Sell at Goldman

via: SeekingAlpha at 2018-12-18 17:52:31:000

Recent checks show ALKS-3831 is "unlikely to be practice changing" for schizophrenia, says analyst Terence Flynn, downgrading Alkermes (NASDAQ: ALKS ) to Sell from Neutral. More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes cut to Sell at Goldman

via: SeekingAlpha at 2018-12-18 17:52:31:000

Recent checks show ALKS-3831 is "unlikely to be practice changing" for schizophrenia, says analyst Terence Flynn, downgrading Alkermes (NASDAQ: ALKS ) to Sell from Neutral. More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes cut to Sell at Goldman

via: SeekingAlpha at 2018-12-18 17:52:31:000

Recent checks show ALKS-3831 is "unlikely to be practice changing" for schizophrenia, says analyst Terence Flynn, downgrading Alkermes (NASDAQ: ALKS ) to Sell from Neutral. More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS

via: SeekingAlpha at 2018-12-17 08:02:46:000

Alkermes plc (NASDAQ: ALKS ) has filed a New Drug Application (NDA) with the FDA seeking approval for VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Alkermes plc, Biogen Inc., Healthcare stocks news, Read more … read more...

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS

via: SeekingAlpha at 2018-12-17 08:02:46:000

Alkermes plc (NASDAQ: ALKS ) has filed a New Drug Application (NDA) with the FDA seeking approval for VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Alkermes plc, Biogen Inc., Healthcare stocks news, Read more … read more...

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS

via: SeekingAlpha at 2018-12-17 08:02:46:000

Alkermes plc (NASDAQ: ALKS ) has filed a New Drug Application (NDA) with the FDA seeking approval for VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Alkermes plc, Biogen Inc., Healthcare stocks news, Read more … read more...

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

via: PR Newswire at 2018-12-17 07:30:00:000

DUBLIN and CAMBRIDGE, Massachusetts , Dec. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc.(Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate&#xA… read more...

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

via: PR Newswire at 2018-12-17 07:30:00:000

DUBLIN and CAMBRIDGE, Massachusetts , Dec. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc.(Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate&#xA… read more...

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

via: PR Newswire at 2018-12-17 07:30:00:000

DUBLIN and CAMBRIDGE, Massachusetts , Dec. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc.(Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate&#xA… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS … read more...

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS … read more...

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS … read more...

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock… read more...

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock… read more...

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock… read more...

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the tre… read more...

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the tre… read more...

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the tre… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc - ALKS

via: Business Wire at 2018-11-15 16:13:00:000

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc. (NASDAQ:ALKS) resulting from allegations that Alkermes may have issued materially misleading business information to the investing publ… read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

NEW YORK , Nov. 9, 2018 /PRNewswire/ --Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc("Alkermes" or the "Company") (NASDAQ: ALKS) resulting from allegations t… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

NEW YORK , Nov. 9, 2018 /PRNewswire/ --Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc("Alkermes" or the "Company") (NASDAQ: ALKS) resulting from allegations t… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

NEW YORK , Nov. 9, 2018 /PRNewswire/ --Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc("Alkermes" or the "Company") (NASDAQ: ALKS) resulting from allegations t… read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov. 13, 2018 at 10:20 a.m. MT ( 12:20 p.m. ET / 5:20 p.m. GMT ) from Sco… read more...

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov. 13, 2018 at 10:20 a.m. MT ( 12:20 p.m. ET / 5:20 p.m. GMT ) from Sco… read more...

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov. 13, 2018 at 10:20 a.m. MT ( 12:20 p.m. ET / 5:20 p.m. GMT ) from Sco… read more...

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes plc ( ALKS +3.1% ) is up on modestly higher volume on the heels of its announcement of early-stage data on ALKS 4230 that will be presented at SITC this week. More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, , Read more … read more...

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes plc ( ALKS +3.1% ) is up on modestly higher volume on the heels of its announcement of early-stage data on ALKS 4230 that will be presented at SITC this week. More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, , Read more … read more...

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes plc ( ALKS +3.1% ) is up on modestly higher volume on the heels of its announcement of early-stage data on ALKS 4230 that will be presented at SITC this week. More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, , Read more … read more...

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting in Washington, D.C. , Nov. 9-11, 2018 . Initial clinical data from the ongoing monothera… read more...

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting in Washington, D.C. , Nov. 9-11, 2018 . Initial clinical data from the ongoing monothera… read more...

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting in Washington, D.C. , Nov. 9-11, 2018 . Initial clinical data from the ongoing monothera… read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Headquartered in Dublin, Ireland, Alkermes (ALKS) is mainly focused on developing and commercializing therapies targeting conditions such as schizophrenia, depression, addiction, and multiple sclerosis, a ll of which the company characterizes as the central nervous system, or CNS, disorders. … read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Headquartered in Dublin, Ireland, Alkermes (ALKS) is mainly focused on developing and commercializing therapies targeting conditions such as schizophrenia, depression, addiction, and multiple sclerosis, a ll of which the company characterizes as the central nervous system, or CNS, disorders. … read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Headquartered in Dublin, Ireland, Alkermes (ALKS) is mainly focused on developing and commercializing therapies targeting conditions such as schizophrenia, depression, addiction, and multiple sclerosis, a ll of which the company characterizes as the central nervous system, or CNS, disorders. … read more...

Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder

via: PR Newswire at 2018-11-01 18:47:00:000

DUBLIN , Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the company's … read more...

FDA Ad Com thumbs down on Alkermes' buprenorphine/samidorphan

via: SeekingAlpha at 2018-11-01 16:01:55:000

FDA advisory committees voted 20-3 against approval for Alkermes' (NASDAQ: ALKS ) buprenorphine and samidorphan sublingual tablets for the adjunctive treatment of major depressive disorder. More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

Trading in Alkermes Ordinary Shares Halted Today

via: PR Newswire at 2018-11-01 07:00:00:000

DUBLIN , Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Comm… read more...

Alkermes down 6% premarket ahead of Ad Com for buprenorphine/samidorphan for MDD

via: SeekingAlpha at 2018-10-30 08:04:40:000

Alkermes plc (NASDAQ: ALKS ) is down 6% premarket on light volume in response to the release of briefing documents for Thursday's FDA advisory committee meeting to review and discuss its marketing application seeking approval for buprenorphine and samidorphan sublingual tablets… read more...

Alkermes down 6% premarket ahead of Ad Com for buprenorphine/samidorphan for MDD

via: SeekingAlpha at 2018-10-30 08:04:40:000

Alkermes plc (NASDAQ: ALKS ) is down 6% premarket on light volume in response to the release of briefing documents for Thursday's FDA advisory committee meeting to review and discuss its marketing application seeking approval for buprenorphine and samidorphan sublingual tablets… read more...

Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry

via: PR Newswire at 2018-10-29 13:19:00:000

ALKS 5461 DemonstratedConsistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies New Drug Application for ALKS 5461 Currently Under FDA Review With Target Action Date of Jan. 31, 2019 DUBLIN , … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of an aggregate of $1 millionin grants for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and s… read more...

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of an aggregate of $1 millionin grants for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and s… read more...

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of an aggregate of $1 millionin grants for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and s… read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

Alkermes (ALKS) CEO Richard Pops on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-23 15:17:04:000

Alkermes Plc (ALKS) Q3 2018 Earnings Conference Call October 23, 2018 8:30 AM ET Executives Sandy Coombs Co-Head of Investor Relations Jim Frates Senior Vice President, Chief Financial Officer and Treasurer Richard Pops Chairman and Chief Executive Offi… read more...

Alkermes plc 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-23 10:16:06:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q3 earnings Read more … read more...

Alkermes Q3 revenues up 14%

via: SeekingAlpha at 2018-10-23 07:50:20:000

Alkermes ( ALKS ) Q3 results: Revenues: $248.7M (+14.4%); Manufacturing and royalty revenues: $116.4M (-5.1%); Product sales: $116M (+23.8%); R&D revenue: $16.3M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Alkermes beats by $0.14, beats on revenue

via: SeekingAlpha at 2018-10-23 07:01:41:000

Alkermes (NASDAQ: ALKS ): Q3 Non-GAAP EPS of $0.07 beats by $0.14 ; GAAP EPS of -$0.22 beats by $0.24 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports Third Quarter 2018 Financial Results

via: PR Newswire at 2018-10-23 07:00:00:000

Third Quarter Revenues Increased to $248.7 Million , Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports GAAP Net Loss per Share of $0.22 and Diluted Non-GAAP Earnings per Share of $0.07 &#… read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-10-22 17:30:35:000

ABG , ALKS , ARCH , ASTE , ATI , AVY , AXE , BIIB , CAT , CIT , CNC , DGX , EDU , FBC , FITB , FNB , GATX , GLW , GPK , HBAN , HOG , HUBB , JBLU , LMT , LPT , MBFI , MCD , MMM , NEE , PCAR , PHM , PNR , PPBI , RF , SLCA , SNV , TRU , UTX , VZ , WAT , … read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, 2018 . Poster presentations will include clinical and real-world data related… read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, 2018 . Poster presentations will include clinical and real-world data related… read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, 2018 . Poster presentations will include clinical and real-world data related… read more...

Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results

via: PR Newswire at 2018-10-16 16:01:00:000

DUBLIN , Oct. 16, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Tuesday, Oct. 23, 2018 , to discuss the company's third quarter 2018 financial results. Management will also provide an up… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes plc (NASDAQ: ALKS ) has expanded its Phase 1 clinical trial assessing ALKS 4230 in patients with advanced solid tumors to include a combination with Merck's (NYSE: MRK ) KEYTRUDA (pembrolizumab). More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes plc (NASDAQ: ALKS ) has expanded its Phase 1 clinical trial assessing ALKS 4230 in patients with advanced solid tumors to include a combination with Merck's (NYSE: MRK ) KEYTRUDA (pembrolizumab). More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes plc (NASDAQ: ALKS ) has expanded its Phase 1 clinical trial assessing ALKS 4230 in patients with advanced solid tumors to include a combination with Merck's (NYSE: MRK ) KEYTRUDA (pembrolizumab). More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the F… read more...

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the F… read more...

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the F… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

via: PR Newswire at 2018-09-05 07:00:00:000

--ALKERMES Inspiration Grants Program Will Award Up to$1 Millionfor the Development or Expansion of Innovative Programs-- --Applications Now Open for Submission ThroughOct. 2, 2018-- DUBLIN , Sept. 5, 2018 /PRNews… read more...

Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

via: PR Newswire at 2018-09-05 07:00:00:000

--ALKERMES Inspiration Grants Program Will Award Up to$1 Millionfor the Development or Expansion of Innovative Programs-- --Applications Now Open for Submission ThroughOct. 2, 2018-- DUBLIN , Sept. 5, 2018 /PRNews… read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA clamps down on opioid-peddling websites

via: SeekingAlpha at 2018-08-28 10:57:45:000

The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc… read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

FDA awards contract to develop guidelines for opioid prescribing

via: SeekingAlpha at 2018-08-22 11:16:23:000

The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

White House proposing cuts in opioid production

via: SeekingAlpha at 2018-08-16 15:24:55:000

Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET ( 3:30 p.m. BST ) from Boston . The prese… read more...

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET ( 3:30 p.m. BST ) from Boston . The prese… read more...

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET ( 3:30 p.m. BST ) from Boston . The prese… read more...

Alkermes - 2018 Shaping Into Excellent Year

via: SeekingAlpha at 2018-07-30 08:49:44:000

Alkermes ( ALKS ) recently reported Q2, 2018 earnings. With solid revenues and significant near term catalysts, 2018 is turning into an excellent year. This article explores Alkermes' investment merits. Alkermes' Vivitrol generates solid increasing revenues. Alkermes' Vivitrol is an oldie … read more...

Alkermes - 2018 Shaping Into Excellent Year

via: SeekingAlpha at 2018-07-30 08:49:44:000

Alkermes ( ALKS ) recently reported Q2, 2018 earnings. With solid revenues and significant near term catalysts, 2018 is turning into an excellent year. This article explores Alkermes' investment merits. Alkermes' Vivitrol generates solid increasing revenues. Alkermes' Vivitrol is an oldie … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Sandra Coombs - Alkermes Plc James M. Frates - Alkermes Plc James Robinson - Alkermes Plc Richard F. Pops - Alkermes Plc Analysts Cameron Allen Bradshaw - Bank of America Merrill Lynch Chris S… read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Sandra Coombs - Alkermes Plc James M. Frates - Alkermes Plc James Robinson - Alkermes Plc Richard F. Pops - Alkermes Plc Analysts Cameron Allen Bradshaw - Bank of America Merrill Lynch Chris S… read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Sandra Coombs - Alkermes Plc James M. Frates - Alkermes Plc James Robinson - Alkermes Plc Richard F. Pops - Alkermes Plc Analysts Cameron Allen Bradshaw - Bank of America Merrill Lynch Chris S… read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 -- -- Company Rei… read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 -- -- Company Rei… read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 -- -- Company Rei… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-07-25 17:30:13:000

AAL , AAN , AB , ABMD , ADNT , AGN , AIMC , ALK , ALKS , ALLE , ALLY , ALXN , APD , ARD , ASPS , AUO , AXE , AXTA , AZN , BANC , BAX , BC , BMS , BMY , BUD , BWA , CELG , CFR , CMCSA , CME , CMS , CNHI , COLB , COP , COR , COWN , CPG , CRI , CRR , CTS… read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's second quarter 2018 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's second quarter 2018 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's second quarter 2018 financial results. Management will also provide an … read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

FDA Approves ARISTADA INITIO(TM) for the Initiation of ARISTADA® for Schizophrenia

via: PR Newswire at 2018-07-02 07:01:00:000

DUBLIN , July 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injec… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

SAGE Therapeutics (NASDAQ: SAGE ) initiated with Buy rating and $230 (49% upside) price target at Ladenburg Thalmann. More news on: Sage Therapeutics, Alkermes plc, Inogen, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

SAGE Therapeutics (NASDAQ: SAGE ) initiated with Buy rating and $230 (49% upside) price target at Ladenburg Thalmann. More news on: Sage Therapeutics, Alkermes plc, Inogen, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

SAGE Therapeutics (NASDAQ: SAGE ) initiated with Buy rating and $230 (49% upside) price target at Ladenburg Thalmann. More news on: Sage Therapeutics, Alkermes plc, Inogen, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes plc (NASDAQ: ALKS ) has received a $50M payment from licensee Biogen (NASDAQ: BIIB ) after the latter's review of preliminary GI tolerability data on BIIB098 (formerly ALKS 8700), an oral fumarate in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (M… read more...

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes plc (NASDAQ: ALKS ) has received a $50M payment from licensee Biogen (NASDAQ: BIIB ) after the latter's review of preliminary GI tolerability data on BIIB098 (formerly ALKS 8700), an oral fumarate in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (M… read more...

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes plc (NASDAQ: ALKS ) has received a $50M payment from licensee Biogen (NASDAQ: BIIB ) after the latter's review of preliminary GI tolerability data on BIIB098 (formerly ALKS 8700), an oral fumarate in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (M… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile New Drug Application Anticipated for Submission in Q4 2018 DUBLIN , June 6, 2018 /PRNewswire… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile New Drug Application Anticipated for Submission in Q4 2018 DUBLIN , June 6, 2018 /PRNewswire… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (d… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile New Drug Application Anticipated for Submission in Q4 2018 DUBLIN , June 6, 2018 /PRNewswire… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (d… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (d… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinica… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami , May 29 June 1, 2018 . The poster presentations will high… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami , May 29 June 1, 2018 . The poster presentations will high… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinica… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami , May 29 June 1, 2018 . The poster presentations will high… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinica… read more...

FDA OKs first non-opioid treatment for opioid withdrawal

via: SeekingAlpha at 2018-05-16 16:44:42:000

The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...

FDA OKs first non-opioid treatment for opioid withdrawal

via: SeekingAlpha at 2018-05-16 16:44:42:000

The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes (ALKS) Webinar On ALKS 3831 Drug - Slideshow

via: SeekingAlpha at 2018-05-11 13:34:33:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes (ALKS) Webinar On ALKS 3831 Drug - Slideshow

via: SeekingAlpha at 2018-05-11 13:34:33:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-11 07:48:03:000

Dexcom (NASDAQ: DXCM ) initiated with Buy rating and $100 (18% upside) price target at BofA/Merrill Lynch. More news on: DexCom, Inc., Alkermes plc, National Health Investors Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-11 07:48:03:000

Dexcom (NASDAQ: DXCM ) initiated with Buy rating and $100 (18% upside) price target at BofA/Merrill Lynch. More news on: DexCom, Inc., Alkermes plc, National Health Investors Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Lundbeck Gets An Unexpected Boon From The FDA

via: SeekingAlpha at 2018-05-04 14:58:14:000

Things really do seem a little different at the FDA these days. The FDA's commissioner, Scott Gottlieb, has talked openly of wanting the agency to take a different approach to its interactions with the biopharma industry, speeding up processes, removing certain roadblocks, and generally shifti… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-04 09:51:27:000

Noteworthy events during the week of May 6 - 12 for healthcare investors. More news on: Lipocine Inc., Neurovive Pharmaceutical AB, Akcea Therapeutics, Healthcare stocks news, Read more … read more...

Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research

via: PR Newswire at 2018-05-04 07:00:00:000

-- ALKERMES Pathways Research Awards(SM) Program Will Provide Up to $400,000 for Projects Focused on Substance Use Disorder -- -- Applications Open for Submission Now Through Aug. 5, 2018 -- DUBLIN , May 4, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announce… read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-02-13 17:30:16:000

ACCO , AER , AGIO , ALKS , BG , CIGI , CIM , CMS , CRTO , CYRN , DNOW , DPS , FLIR , FUN , GEO , GRPN , HLT , ICL , ICPT , IPG , IQV , LAD , LECO , MZOR , OMI , ORBK , PLAB , SABR , SHPG , SODA , STNG , SUM , TAP , TCX , TECK , WIX , WYN For Seeking … read more...

Wall Street Breakfast: Infrastructure Details Coming Today

via: SeekingAlpha at 2018-02-12 07:07:40:000

The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...

Wall Street Breakfast: Infrastructure Details Coming Today

via: SeekingAlpha at 2018-02-12 07:07:40:000

The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 31, 2018

via: SeekingAlpha at 2018-02-01 04:01:08:000

Market and sector outlook: Intraday positive reversal in S&P 500 index ( SPY ). Using our VIX indicator, we have a market buy signal and expect a new high before a more meaningful pullback. 10-year yield continued to rise today. Nasdaq Biotechnology Index ( IBB ) was down likely due… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 31, 2018

via: SeekingAlpha at 2018-02-01 04:01:08:000

Market and sector outlook: Intraday positive reversal in S&P 500 index ( SPY ). Using our VIX indicator, we have a market buy signal and expect a new high before a more meaningful pullback. 10-year yield continued to rise today. Nasdaq Biotechnology Index ( IBB ) was down likely due… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 31, 2018

via: SeekingAlpha at 2018-02-01 04:01:08:000

Market and sector outlook: Intraday positive reversal in S&P 500 index ( SPY ). Using our VIX indicator, we have a market buy signal and expect a new high before a more meaningful pullback. 10-year yield continued to rise today. Nasdaq Biotechnology Index ( IBB ) was down likely due… read more...

Alkermes files U.S. marketing application for MDD med ALKS 5461

via: SeekingAlpha at 2018-01-31 15:02:13:000

Alkermes plc ( ALKS -0.1% ) completes the filing of its New Drug Application (NDA) to the FDA seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes files U.S. marketing application for MDD med ALKS 5461

via: SeekingAlpha at 2018-01-31 15:02:13:000

Alkermes plc ( ALKS -0.1% ) completes the filing of its New Drug Application (NDA) to the FDA seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes files U.S. marketing application for MDD med ALKS 5461

via: SeekingAlpha at 2018-01-31 15:02:13:000

Alkermes plc ( ALKS -0.1% ) completes the filing of its New Drug Application (NDA) to the FDA seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:15:00:000

- New Medicine for Treating Major Depressive Disorder Supported by Comprehensive Efficacy and Safety Data Package From More Than 1,500 Patients - DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:15:00:000

- New Medicine for Treating Major Depressive Disorder Supported by Comprehensive Efficacy and Safety Data Package From More Than 1,500 Patients - DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:15:00:000

- New Medicine for Treating Major Depressive Disorder Supported by Comprehensive Efficacy and Safety Data Package From More Than 1,500 Patients - DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:01:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the a… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:01:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the a… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:01:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the a… read more...

Alkermes: A Solid CNS Portfolio With An Option For Depression

via: SeekingAlpha at 2018-01-29 14:15:39:000

Alkermes Overview Alkermes ( ALKS ) is a Central Nervous System (NYSE: CNS ) focused biotech that is based in Dublin, Ireland and also has locations in Massachusetts and Ohio. It has been led by Richard Pops as CEO since 1991. Leadership of Alkermes consists of 17 people including 2 MD'… read more...

Alkermes: A Solid CNS Portfolio With An Option For Depression

via: SeekingAlpha at 2018-01-29 14:15:39:000

Alkermes Overview Alkermes ( ALKS ) is a Central Nervous System (NYSE: CNS ) focused biotech that is based in Dublin, Ireland and also has locations in Massachusetts and Ohio. It has been led by Richard Pops as CEO since 1991. Leadership of Alkermes consists of 17 people including 2 MD'… read more...

Alkermes: A Solid CNS Portfolio With An Option For Depression

via: SeekingAlpha at 2018-01-29 14:15:39:000

Alkermes Overview Alkermes ( ALKS ) is a Central Nervous System (NYSE: CNS ) focused biotech that is based in Dublin, Ireland and also has locations in Massachusetts and Ohio. It has been led by Richard Pops as CEO since 1991. Leadership of Alkermes consists of 17 people including 2 MD'… read more...

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

via: SeekingAlpha at 2018-01-25 14:10:20:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This… read more...

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

via: SeekingAlpha at 2018-01-25 14:10:20:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This… read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm

via: Business Wire at 2018-01-17 18:08:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc (Alkermes or the Company) (NASDAQ:ALKS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been f… read more...

Scott+Scott, Attorneys at Law, LLP Reminds Investors of January 22 Deadline in Securities Class Action Against Alkermes plc (ALKS)

via: Business Wire at 2018-01-17 13:12:00:000

Scott+Scott, Attorneys at Law, LLP (Scott+Scott), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit is pending against Alkermes plc (NASDAQ: ALKS) (Alkermes or the Company) and certain of… read more...

Your Daily Pharma Scoop: Roche Highlights Pipeline, GenSight Gets Nod To Start Trial, Bluebird Presents At JPM

via: SeekingAlpha at 2018-01-11 03:13:18:000

Analysis of top Seeking Alpha coverage: Roche Today we will focus on Roche ( OTCQX:RHHBY ), which is one of our favorite companies in the large cap biopharma space. The Swiss drugmaker had a solid 2017, gaining more than 10%. While this is below the performance of the IBB for 2017 (up 21… read more...

Alkermes (ALKS) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-10 13:39:39:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes sees 2017 top line as high as $900M

via: SeekingAlpha at 2018-01-10 06:59:03:000

In a presentation at JPM18 yesterday, Alkermes (NASDAQ: ALKS ) CEO Richard Pops updated the company's 2017 guidance. More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm

via: Business Wire at 2018-01-09 18:23:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc (Alkermes or the Company) (NASDAQ:ALKS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been f… read more...

What Is Driving Stocks? - Cramer's Mad Money (1/8/18)

via: SeekingAlpha at 2018-01-09 07:44:05:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 8. As the market went higher on Monday, Cramer deduced the reasons for the rally. "First, let's understand: this market is largely driven not by stock-pickers, but by index funds. That index… read more...

Cramer Remix: Tesla's stock is up for one simple reason

via: CNBC at 2018-01-08 19:00:00:000

No summary available. read more...

'Best days are still ahead' for top opioid addiction treatment Vivitrol, CEO says

via: CNBC at 2018-01-08 18:42:00:000

No summary available. read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX